
Axonics Modulation Technologies AXNX
Quarterly report 2024-Q3
added 11-07-2024
Axonics Modulation Technologies Total Assets 2011-2026 | AXNX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Axonics Modulation Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 659 M | 548 M | 342 M | 220 M | 172 M | 29.4 M | 10.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 659 M | 10.9 M | 283 M |
Quarterly Total Assets Axonics Modulation Technologies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 774 M | 747 M | 716 M | 720 M | - | 649 M | - | 659 M | 632 M | - | 526 M | 548 M | 561 M | 566 M | 445 M | 342 M | 342 M | 342 M | 342 M | 220 M | 220 M | 220 M | 220 M | 172 M | 172 M | 172 M | 172 M | 29.4 M | 29.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 774 M | 29.4 M | 405 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 1.98 | -4.81 % | $ 1.2 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
Electromed
ELMD
|
53.8 M | $ 25.1 | -2.49 % | $ 212 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 13.08 | -2.24 % | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Pulmonx Corporation
LUNG
|
129 M | $ 1.2 | -2.04 % | $ 48.8 M | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Orthofix Medical
OFIX
|
851 M | $ 11.49 | -3.53 % | $ 455 M | ||
|
EDAP TMS S.A.
EDAP
|
77.2 M | $ 3.36 | 1.66 % | $ 126 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
3.19 B | $ 160.02 | -12.5 % | $ 11.3 B | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.64 | 5.95 % | $ 39.8 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 10.34 | -6.68 % | $ 293 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Globus Medical
GMED
|
5.3 B | $ 87.79 | -3.25 % | $ 11.9 B | ||
|
Sintx Technologies
SINT
|
9.51 M | $ 1.99 | -7.44 % | $ 5.52 M | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
TELA Bio
TELA
|
81.4 M | $ 0.86 | 10.26 % | $ 40.4 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Tandem Diabetes Care
TNDM
|
881 M | $ 18.16 | -2.52 % | $ 1.24 B | ||
|
Butterfly Network
BFLY
|
256 M | $ 4.92 | -4.47 % | $ 1.04 B | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 14.64 | -3.3 % | $ 343 M | ||
|
Delcath Systems
DCTH
|
124 M | $ 10.21 | -3.22 % | $ 366 M | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.03 | -0.96 % | $ 17.4 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 35.96 | -2.26 % | $ 1.12 B | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 58.92 | -3.87 % | $ 3.21 B | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 53.41 | -3.08 % | $ 1.57 B | ||
|
LENSAR
LNSR
|
71.4 M | $ 5.39 | 0.75 % | $ 64.5 M | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 83.67 | -1.15 % | $ 2.91 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Varex Imaging Corporation
VREX
|
1.11 B | $ 11.03 | -8.62 % | $ 457 M | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 81.22 | -1.29 % | $ 47.5 B | ||
|
Tactile Systems Technology
TCMD
|
274 M | $ 22.5 | -4.54 % | $ 515 M |